Thomas A. Bologna is an experienced Chairman, President and Chief Executive Officer in leading public, venture and private equity backed diagnostic, pharmaceutical, device and clinical laboratory testing healthcare companies including turnarounds and start-ups, many of which he sold and/or took public.
Mr. Bologna was Chairman of the Board and Chief Executive Officer of Response Genetics, Inc., a clinical laboratory company, President and Chief Executive Officer of Orchid Cellmark, Inc., a leading DNA testing services company with operations in the United States and Europe, President and Chief Executive Officer
of Quorex Pharmaceuticals, Chairman of the Board, President and Chief Executive Officer of Ostex International, Inc., a company that developed and commercialized products for the therapeutic management of osteoporosis and Chairman of the Board, President and Chief Executive Officer of Gen-Probe, Incorporated, a highly successful molecular diagnostics company.
Mr. Bologna also held senior level positions at highly profitable healthcare divisions and subsidiaries of Fortune 500 companies including President of the Becton Dickinson Diagnostic Instrument Systems Division. He was also a founder and member of the Sponsoring Committee of the venture capital firm, Mission Ventures.
Mr. Bologna received his B.S. from the New York University School of Engineering and Science and his M.B.A. from the New York University Graduate School of Business Administration.
Bill Huffnagle, Director
Bill Huffnagle brings over 29 years of Med Tech healthcare experience to CDx Diagnostics. Most recently, Bill was President of the $3B Reconstructive Division at Stryker Orthopaedics which included the global joint replacement business including hips, knees, robotics and Performance Solutions. He is a driven and innovative executive known for leading growth and capitalizing on market opportunities in complex and global environments. He has a proven record of creating clear goals and operational strategies to deliver strong returns, with an emphasis on market expansion, portfolio and product management.
During his tenure at Stryker, Mr. Huffnagle spearheaded the integration of Mako Surgical, the acquisition propelling Stryker to lead the world in orthopedic robotic-assisted surgery. Bill brings exceptional customer relationship skills, strategic thinking and drive for results to CDx. He has demonstrated the ability to build and develop strong teams and challenge the status quo to bring new, innovative approaches to drive business growth.
Bill has worked at all levels of the Med Tech industry starting in 1988 as a Sales Representative for Howmedica in the Orthopaedics reconstructive market. As VP/GM of Stryker’s Hip portfolio, he managed distribution and sales organizations, global R&D projects and marketing strategy.
Mark Rutenberg, Director
Mark Rutenberg has devoted the last 20 years to the development, management and marketing of medical diagnostics, with particular concentration in application of advanced digital image processing techniques to anatomic pathology.
He pioneered the application to medicine of advanced image processing techniques originally developed for missile defense, and is the author of over a dozen patents in the areas of neural networks, image analysis and medical imaging. Mark has founded two companies in this area. He led his first company, Neuromedical Systems, in what was described by Fortune magazine as “the most successful medical technology IPO of the 1990s.”
When he left Neuromedical in June of 1997 it was projected to break even within the year with cash reserves in excess of $80M, and its technology for enhancing the accuracy of cervical Pap smears had been adopted by over 250 major US laboratories with another 50 laboratories on a waiting list for training. Mark is a recipient of the Ernst & Young Entrepreneur of the year award in the Life Sciences.
Stephen J. Balog, Director
Mr. Balog has over 30 years of investment-related experience. From 1983 to 2002, Mr. Balog was an equity analyst and research executive. He was recognized 5 years running by the Institutional Investor magazine’s All-American research poll for his work on the electronics industry while at Prudential Bache and Shearson Lehman Brothers.
In 1990, he moved into research management at Lehman Brothers. In 1995, he joined Furman Selz as a Director of Research and drove the rapid buildup of the firm’s research department prior to the firm’s sale to ING Barings. After working on an entrepreneurial endeavor, Mr. Balog joined Merrill Lynch in 2000 to lead the research efforts in the global technology industry. After leaving Merrill Lynch, in 2002, Mr. Balog joined Cedar Creek Management, a value-oriented, long/short investment partnership based in Summit, New Jersey, where he served as a partner through the partnership’s close in 2009. From 2010 to 2011, Mr. Balog was Chief Investment Officer at Beacon Trust Company.
After leaving Beacon Trust, Mr. Balog has focused on making private equity and venture capital investments. Mr. Balog holds a BS in Mechanical Engineering from Bucknell University and an MBA in Finance from the University of Pennsylvania’s Wharton School. Mr. Balog is currently active or has served on various non-profit boards, including the NY Society of Security Analysts, the Citizens Campaign (treasurer), Covenant House, Kemmerer Library, Harding Township (president, treasurer and investment committee chair), Harding Township Civic Association and St. Joseph’s High School, Metuchen (trustee and foundation).
On the for-profit side, Mr. Balog was a trustee of Lehman Brothers Employee Pension Fund and was on the board of Furman Selz, LLC. Mr. Balog is currently a member of the Audit Committee, Nominating and Governance Committee, Compliance Committee, and Valuation Committee (Chair – effective May 4, 2016) of the Trust’s Board of Trustees.
David Jahns, Director
Mr. Jahns is a Managing Director of Galen Partners. With over 25 years of experience in building healthcare companies, he is passionate about working collaboratively with innovative management teams to create novel solutions that improve healthcare quality and safety for patients while reducing the cost of delivery to the system. With experience in over 70 growth equity investments, Mr. Jahns has developed substantial expertise and leadership in working with entrepreneurs to build market-leading healthcare companies in the areas of technology-enabled services, medical devices, medical robotics, diagnostics, consumer driven healthcare, telemedicine, clinical decision support, and health information technology and SaaS solutions. The following are market-leading healthcare companies in which Mr. Jahns has taken a leadership role: CBL Path, Chamberlin Edmonds, Eduneering, Encore Medical, InTouch Health, lifeIMAGE, MedAssets, MiniMed, Ocular Sciences, PeriGen, Pyxis, Sharecare, Stericycle, Unisyn Medical Technologies and SonaCare.
Prior to joining Galen in 1993, Mr. Jahns was an investment banker and financial advisor to healthcare companies. He worked in the Corporate Finance Department at Smith Barney, Inc. in New York, specializing in public offerings and mergers and acquisitions, as well as public debt financings. As an investment banker and venture capitalist, Mr. Jahns has worked on more than 20 initial public offerings, including 11 IPOs of Galen’s portfolio companies. Additionally, he has extensive M&A experience, including 19 sales to financial and strategic buyers of Galen’s portfolio companies.
Mr. Jahns has served on numerous public and private company boards of directors. He is a member of the Board of Directors and the Quality and Clinical Affairs Committee of Stamford Health System, Inc. He is a frequent speaker at various healthcare industry conferences on healthcare market trends and the healthcare technology-enabled outsourcing industry. He is also a guest lecturer at the Kellogg School of Management and mentor to the Kellogg Venture Lab program. He also serves on several non-profit boards of directors for various community and philanthropic corporations.
Mr. Jahns earned an M.B.A. from the Northwestern University, Kellogg School of Management, where he specialized in Health Services Management. He earned his B.A. in political science and economics from Colgate University, where he graduated Phi Beta Kappa.
John Watts, Director
Mr. John Watts has more than 30 years of experience in building, growing and leading large health plan organizations. His experience includes leading successful organizations to higher growth targets, through turnaround situations, and building successful new ventures. John also has significant experience managing P&L for large enterprises.
John spent 12 years at WellPoint, the nation’s largest insurer with approximately 35 million members, where he held numerous executive positions, including chief executive and president of Blue Cross Blue Shield of Georgia and president and CEO of National Accounts. In his most recent position as president and CEO of WellPoint’s Commercial and Consumer Business, he directed a $50 billion division that encompassed 14 Blue Cross Blue Shield plans.
John is currently on the board of a number of healthcare related companies including, Blue Cross and Blue Shield of Minnesota, Paradigm Outcomes and Zenith American. In addition, he facilitates roundtable discussions with CEO’s from across the healthcare industry as a Managing Director of the Center for Corporate Innovation.
He earned his BA in English from the University of California, Los Angeles (UCLA).